drugset / Trial / NCT05909072
Tranexamic Acid With Microneedling in Melasma
RandomizedParallel-groupSingle-blindTreatment
Summary
Topical tranexamic, a hydrophilic molecule, can't pass the lipid barriers of the stratum corneum and it's also not retained in adequate amount in the epidermis to enter the melanocytes, so there's a difficulty in the effective delivery of tranexamic acid into the melanocytes . Hyaluronic acid was proved to improve the effective delivery of tranexamic acid through loosening corneocyte packing and helping TXA entering the melanocytes and minimizing its epidermal diffusion .
Timeline
- Start
- 2023-06
- Primary completion
- 2023-11
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hyaluronic Acid | Other / unclassified | 0.5 ml | — |
| Comparator | Tranexamic Acid | Small molecule | 1 ml | Topical |